Drug intelligence / Profile preview

R-(-)-FPFS-1183

Development stage
Preclinical
Lead developer
Fujimoto Seiyaku
Modality
Small Molecules
Administration
Oral
01

Overview

R-(-)-FPFS-1183 is a synthetic small molecule and a member of the benzofuranyl-propylaminopentane (BPAP) derivative series. It functions as a catecholaminergic and serotoninergic activity enhancer (CAE/SAE), a unique pharmacological class that selectively increases the impulse-evoked release of dopamine and serotonin in the central nervous system. Developed by Fujimoto Pharmaceutical, R-(-)-FPFS-1183 is the R-enantiomer of the 5-fluoro analogue of BPAP. It has demonstrated potent neuroprotective effects in preclinical models, primarily through the induction of the anti-apoptotic protein Bcl-2 and the stabilization of mitochondrial membrane potential. These properties make it a candidate for the treatment of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, as well as psychiatric conditions like depression, where it aims to restore monoaminergic signaling without the risk of neurotransmitter depletion or excessive non-impulse-related release.

Other names
(-)-1-(5-fluorobenzofuran-2-yl)-2-propylaminopentaneR-(-)-1-(5-fluorobenzofuran-2-yl)-2-propylaminopentane
02

Targets

Monoaminergic activity enhancer site (MAE site)ADRA2A (α2A)BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on R-(-)-FPFS-1183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-(-)-FPFS-1183.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call